- Home
- HCM vs APLS Comparison
HCM vs APLS Comparison
Compare HCM & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- APLS
- Stock Information
- Founded
- HCM 2000
- APLS 2009
- Country
- HCM Hong Kong
- APLS United States
- Employees
- HCM N/A
- APLS N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- HCM Health Care
- APLS Health Care
- Exchange
- HCM Nasdaq
- APLS Nasdaq
- Market Cap
- HCM 2.6B
- APLS 2.9B
- IPO Year
- HCM N/A
- APLS 2017
- Fundamental
- Price
- HCM $15.10
- APLS $28.71
- Analyst Decision
- HCM Sell
- APLS Buy
- Analyst Count
- HCM 1
- APLS 19
- Target Price
- HCM $13.75
- APLS $33.63
- AVG Volume (30 Days)
- HCM 43.6K
- APLS 2.4M
- Earning Date
- HCM 08-07-2025
- APLS 10-30-2025
- Dividend Yield
- HCM N/A
- APLS N/A
- EPS Growth
- HCM N/A
- APLS N/A
- EPS
- HCM 0.53
- APLS N/A
- Revenue
- HCM $602,197,000.00
- APLS $754,649,000.00
- Revenue This Year
- HCM N/A
- APLS $21.75
- Revenue Next Year
- HCM $15.49
- APLS N/A
- P/E Ratio
- HCM $5.61
- APLS N/A
- Revenue Growth
- HCM N/A
- APLS 20.02
- 52 Week Low
- HCM $11.51
- APLS $16.10
- 52 Week High
- HCM $21.50
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- HCM 39.12
- APLS 67.38
- Support Level
- HCM $14.86
- APLS $23.85
- Resistance Level
- HCM $15.34
- APLS $25.73
- Average True Range (ATR)
- HCM 0.32
- APLS 1.29
- MACD
- HCM -0.06
- APLS 0.55
- Stochastic Oscillator
- HCM 7.79
- APLS 98.69
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.